Why the study?
Does a diphtheria toxin-related IL-2 fusion protein prolong allograft survival in a murine heart transplant model?
Does a diphtheria toxin-related IL-2 fusion protein prolong allograft survival in a murine heart transplant model?
A chimeric IL-2 toxin targeting activated T cells significantly prolongs cardiac allograft survival in a murine model, suggesting a potential new immunosuppressive strategy.
No immediate clinical implications; leaves open translation of IL-2 toxin efficacy beyond murine allograft models.
A diphtheria toxin-related IL-2 fusion gene has been constructed that encodes a 68KD recombinant toxin in which the diphtheria toxin receptor-binding domain has been replaced with amino acids 2-133 of IL-2. This chimeric IL-2 toxin is cytotoxic for cells expressing the high-affinity IL-2 receptor but not for cells lacking this receptor. The ability of this IL-2 toxin to prolong allograft survival was examined in a murine vascularized, heterotopic heart transplant model in the strain combination B10.BR into C57B1/10. When given at a dose of 1.0 micrograms/day for 10 days, the IL-2 toxin significantly prolonged allograft survival in all recipients. CRM-45, a fragment of diphtheria toxin missing the binding domain, was ineffective, confirming the specificity of the therapy. The results demonstrate that this IL-2 toxin, which targets activated T cells expressing the IL-2 receptor, will prolong allograft survival, offering a new option for immunosuppressive therapy.
No takes yet. Share an insight, caveat, or question.
Kirkman et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: